Cargando…

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer

OBJECTIVE: To compare (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT and (68)Ga-PSMA PET/CT in the diagnostic value of prostate cancer. METHOD: The Chinese and foreign databases, such as Pubmed, Cochrane Library, Embase, CNKI, VIP, Wanfang, etc., were systematically searched within the period from the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Wenxiao, Zhao, Ming, Deng, Yingjun, Liu, Shengjing, Du, Guanchao, Yan, Bin, Zhao, Ziwei, Sun, Ning, Guo, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440897/ https://www.ncbi.nlm.nih.gov/pubmed/37605288 http://dx.doi.org/10.1186/s40644-023-00599-y

Ejemplares similares

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

(68)Ga-PSMA PET/CT Versus (18)F-FDG PET/CT for Imaging of Hepatocellular Carcinoma
por: Gündoğan, Cihan, et al.
Publicado: (2021)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer
por: Zhou, Xing, et al.
Publicado: (2021)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

The Value of (68)Ga-PSMA PET/CT Following Equivocal (18)F-NaF PET/CT in Prostate Cancer Patients
por: Madsen, Claus, et al.
Publicado: (2020)

Comparative Findings Between (68)Ga-PSMA and (18)F-FDG PET/CT for Hepatocellular Carcinoma
por: Erhamamcı, Seval, et al.
Publicado: (2020)

Analysis of Pros and Cons in Using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer
por: Maisto, Costantina, et al.
Publicado: (2022)

Heterogeneous uptake of (18)F-FDG and (18)F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
por: Hu, Yuan, et al.
Publicado: (2023)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
por: Trägårdh, Elin, et al.
Publicado: (2020)

An exploratory study of unexplained concentration of (18)F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging
por: Dang, Jun, et al.
Publicado: (2023)

A randomised, prospective and head-to-head comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
por: Alberts, Ian, et al.
Publicado: (2022)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

The value of (18)F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
por: Hong, Jun-jie, et al.
Publicado: (2020)

Diagnostic Role of (18)F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
por: Awenat, Salam, et al.
Publicado: (2021)

Risk of metastatic disease using [(18)F]PSMA-1007 PET/CT for primary prostate cancer staging
por: Chikatamarla, Venkata Avinash, et al.
Publicado: (2021)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

A randomised trial of [(18)F]PSMA‐1007‐PET/CT versus NaF‐PET/CT for staging primary prostate cancer: A trial protocol
por: Buch‐Olsen, Karen Middelbo, et al.
Publicado: (2023)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

Diagnostic Performance of [(18)F]Fluorocholine and [(68)Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study
por: Paymani, Zeinab, et al.
Publicado: (2020)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Evaluation of (18)F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
por: Zhou, Xing, et al.
Publicado: (2021)

An Explorative Study of the Incidental High Renal Excretion of [(18)F]PSMA-1007 for Prostate Cancer PET/CT Imaging
por: Allach, Youssra, et al.
Publicado: (2022)

Isolated Rectal Metastases from Locally Advanced Carcinoma Prostate Detected by (18) F-PSMA-1007 PET/CT
por: Singh, Shashank Shekhar, et al.
Publicado: (2022)

The (18)F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer
por: Wang, Zhuonan, et al.
Publicado: (2022)

Recurrent Prostate Cancer Diagnostics with (18)F-PSMA-1007 PET/CT: A Systematic Review of the Current State
por: Saule, Laura, et al.
Publicado: (2022)

Evaluating the value of (18)F-PSMA-1007 PET/CT in the detection and identification of prostate cancer using histopathology as the standard
por: Luo, Liang, et al.
Publicado: (2023)

The Heterogeneous Metabolic Patterns of Ganglia in (68)Ga-PSMA, (11)C-choline, and (18)F-FDG PET/CT in Prostate Cancer Patients
por: Shi, Yiping, et al.
Publicado: (2021)

Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
por: Vollnberg, Bernd, et al.
Publicado: (2022)

Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
por: Elboga, Umut, et al.
Publicado: (2022)

Prostate Cancer Biochemical Recurrence Resulted Negative on [(68)Ga]Ga-PSMA-11 but Positive on [(18)F]Fluoromethylcholine PET/CT
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Prospective inter- and intra-tracer repeatability analysis of radiomics features in [(68)Ga]Ga-PSMA-11 and [(18)F]F-PSMA-1007 PET scans in metastatic prostate cancer
por: Kendrick, Jake, et al.
Publicado: (2023)

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2013)

Use of (68)Ga-PSMA-11 and (18)F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia
por: Shi, Yiping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5tjsejuotqhcllb6k460ifa4bk